Peringatan Keamanan

LD50 information for the hepatitis A vaccine is not readily available in the literature.
The prescribing information for the inactivated Hepatitis A vaccine indicates that postmarketing reports of adverse effects following an overdose with the vaccine that were similar to those that are normally expected. This may include pain or redness at the injection site, headache, irritability, appetite loss, and other symptoms. Prescribing information also advises contacting the local poison control center in the case of an overdose.L338

Hepatitis A Vaccine

DB10989

biotech approved

Deskripsi

Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure.A199182 Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.A199185,L12756 In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries.L13392

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

285 Data
Etanercept The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Etanercept.
Peginterferon alfa-2a The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Peginterferon alfa-2a.
Interferon alfa-n1 The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-n1.
Interferon alfa-n3 The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-n3.
Peginterferon alfa-2b The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Peginterferon alfa-2b.
Anakinra The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Anakinra.
Interferon gamma-1b The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon gamma-1b.
Interferon alfa-2a The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-2a.
Aldesleukin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Aldesleukin.
Adalimumab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Adalimumab.
Gemtuzumab ozogamicin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.
Pegaspargase The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pegaspargase.
Infliximab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Infliximab.
Interferon beta-1b The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon beta-1b.
Interferon alfacon-1 The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfacon-1.
Trastuzumab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trastuzumab.
Rituximab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rituximab.
Basiliximab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Basiliximab.
Muromonab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Muromonab.
Ibritumomab tiuxetan The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.
Tositumomab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tositumomab.
Alemtuzumab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alemtuzumab.
Cyclosporine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclosporine.
Alefacept The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alefacept.
Efalizumab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Efalizumab.
Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-2b.
Natalizumab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Natalizumab.
Daclizumab The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daclizumab.
Phenylalanine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Phenylalanine.
Bortezomib The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bortezomib.
Cladribine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cladribine.
Carmustine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Carmustine.
Amsacrine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Amsacrine.
Bleomycin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bleomycin.
Chlorambucil The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Chlorambucil.
Raltitrexed The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Raltitrexed.
Mitomycin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mitomycin.
Bexarotene The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bexarotene.
Vindesine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vindesine.
Floxuridine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Floxuridine.
Indomethacin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Indomethacin.
Tioguanine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tioguanine.
Vinorelbine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vinorelbine.
Dexrazoxane The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dexrazoxane.
Sorafenib The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sorafenib.
Streptozocin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Streptozocin.
Trifluridine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trifluridine.
Gemcitabine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemcitabine.
Teniposide The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Teniposide.
Epirubicin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Epirubicin.
Chloramphenicol The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Chloramphenicol.
Lenalidomide The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Lenalidomide.
Altretamine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Altretamine.
Zidovudine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Zidovudine.
Cisplatin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cisplatin.
Oxaliplatin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Oxaliplatin.
Cyclophosphamide The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclophosphamide.
Vincristine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vincristine.
Fluorouracil The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluorouracil.
Propylthiouracil The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Propylthiouracil.
Pentostatin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pentostatin.
Methotrexate The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Methotrexate.
Carbamazepine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Carbamazepine.
Vinblastine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Vinblastine.
Linezolid The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Linezolid.
Imatinib The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Imatinib.
Clofarabine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clofarabine.
Pemetrexed The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pemetrexed.
Mycophenolate mofetil The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mycophenolate mofetil.
Daunorubicin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daunorubicin.
Irinotecan The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Irinotecan.
Methimazole The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Methimazole.
Etoposide The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Etoposide.
Sulfasalazine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sulfasalazine.
Dacarbazine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dacarbazine.
Temozolomide The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Temozolomide.
Penicillamine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Penicillamine.
Tacrolimus The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tacrolimus.
Sirolimus The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sirolimus.
Mechlorethamine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mechlorethamine.
Azacitidine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Azacitidine.
Carboplatin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Carboplatin.
Dactinomycin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dactinomycin.
Azathioprine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Azathioprine.
Doxorubicin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Doxorubicin.
Hydroxyurea The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Hydroxyurea.
Busulfan The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Busulfan.
Mycophenolic acid The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mycophenolic acid.
Topotecan The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Topotecan.
Mercaptopurine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Mercaptopurine.
Thalidomide The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Thalidomide.
Melphalan The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Melphalan.
Fludarabine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fludarabine.
Leflunomide The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Leflunomide.
Flucytosine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Flucytosine.
Capecitabine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Capecitabine.
Procarbazine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Procarbazine.
Arsenic trioxide The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Arsenic trioxide.
Idarubicin The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Idarubicin.

Target Protein

B-lymphocytes

Referensi & Sumber

Synthesis reference: Beth Junker John A. Lewis Cynthia Newell Oliver Charles J. Orella Robert D. Sitrin Robert A. Aboud John G. Aunins Barry C. Buckland Peter A. Dephillips Anna J. Hagen John P. Hennessey Jr. Hepatitis A virus vaccine. Patent EP0583142A2. https://patents.google.com/patent/EP0583142A2/en
Artikel (PubMed)
  • PMID: 18159360
    Wu J, Zou S, Giulivi A: Current hepatitis A status in Canada. Can J Infect Dis. 2001 Nov;12(6):341-4. doi: 10.1155/2001/834670.
  • PMID: 12744850
    Demicheli V, Tiberti D: The effectiveness and safety of hepatitis A vaccine: a systematic review. Vaccine. 2003 Jun 2;21(19-20):2242-5. doi: 10.1016/s0264-410x(03)00135-x.

Contoh Produk & Brand

Produk: 43 • International brands: 0
Produk
  • Ambirix
    Injection, suspension • - • Intramuscular • EU • Approved
  • Ambirix
    Injection, suspension • - • Intramuscular • EU • Approved
  • Ambirix
    Injection, suspension • - • Intramuscular • EU • Approved
  • Ambirix
    Injection, suspension • - • Intramuscular • EU • Approved
  • Ambirix
    Injection, suspension • - • Intramuscular • EU • Approved
  • Avaxim
    Suspension • 160 unit / 0.5 mL • Intramuscular • Canada • Approved
  • Avaxim - Pediatric
    Suspension • 80 unit / 0.5 mL • Intramuscular • Canada • Approved
  • Avaxim - Pediatric -(5ml Vial)
    Suspension • 800 unit / 5 mL • Intramuscular • Canada • Approved
Menampilkan 8 dari 43 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul